Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

502 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The pathophysiology of sepsis and precision-medicine-based immunotherapy.
Giamarellos-Bourboulis EJ, Aschenbrenner AC, Bauer M, Bock C, Calandra T, Gat-Viks I, Kyriazopoulou E, Lupse M, Monneret G, Pickkers P, Schultze JL, van der Poll T, van de Veerdonk FL, Vlaar APJ, Weis S, Wiersinga WJ, Netea MG. Giamarellos-Bourboulis EJ, et al. Nat Immunol. 2024 Jan;25(1):19-28. doi: 10.1038/s41590-023-01660-5. Epub 2024 Jan 2. Nat Immunol. 2024. PMID: 38168953 Review.
Towards personalized medicine: a scoping review of immunotherapy in sepsis.
Slim MA, van Mourik N, Bakkerus L, Fuller K, Acharya L, Giannidis T, Dionne JC, Oczkowski SJW, Netea MG, Pickkers P, Giamarellos-Bourboulis EJ, Müller MCA, van der Poll T, Wiersinga WJ; ImmunoSep Consortium; Vlaar APJ, van Vught LA. Slim MA, et al. Among authors: giamarellos bourboulis ej. Crit Care. 2024 May 28;28(1):183. doi: 10.1186/s13054-024-04964-6. Crit Care. 2024. PMID: 38807151 Free PMC article. Review.
Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial.
Dellinger RP, Tomayko JF, Angus DC, Opal S, Cupo MA, McDermott S, Ducher A, Calandra T, Cohen J; Lipid Infusion and Patient Outcomes in Sepsis (LIPOS) Investigators. Dellinger RP, et al. Crit Care Med. 2009 Nov;37(11):2929-38. doi: 10.1097/CCM.0b013e3181b0266c. Crit Care Med. 2009. PMID: 19770753 Clinical Trial.
Early sepsis recognition: how difficult can this be?
Adami ME, Eugen-Olsen J, Giamarellos-Bourboulis EJ. Adami ME, et al. Among authors: giamarellos bourboulis ej. Crit Care. 2024 Jun 5;28(1):190. doi: 10.1186/s13054-024-04975-3. Crit Care. 2024. PMID: 38840224 No abstract available.
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
Kimball AB, Jemec GBE, Sayed CJ, Kirby JS, Prens E, Ingram JR, Garg A, Gottlieb AB, Szepietowski JC, Bechara FG, Giamarellos-Bourboulis EJ, Fujita H, Rolleri R, Joshi P, Dokhe P, Muller E, Peterson L, Madden C, Bari M, Zouboulis CC. Kimball AB, et al. Among authors: giamarellos bourboulis ej. Lancet. 2024 May 22:S0140-6736(24)00101-6. doi: 10.1016/S0140-6736(24)00101-6. Online ahead of print. Lancet. 2024. PMID: 38795716
A Nationwide Study of the Delayed Diagnosis and the Clinical Manifestations of Predominantly Antibody Deficiencies and CTLA4-Mediated Immune Dysregulation Syndrome in Greece.
Kapousouzi A, Kalala F, Sarrou S, Farmaki E, Antonakos N, Kakkas I, Kourakli A, Labropoulou V, Kelaidi C, Tsiouma G, Dimou M, Vassilakopoulos TP, Voulgarelis M, Onoufriadis I, Papadimitriou E, Polychronopoulou S, Giamarellos-Bourboulis EJ, Symeonidis A, Hadjichristodoulou C, Germenis AE, Speletas M. Kapousouzi A, et al. Among authors: giamarellos bourboulis ej. Medicina (Kaunas). 2024 May 8;60(5):782. doi: 10.3390/medicina60050782. Medicina (Kaunas). 2024. PMID: 38792965 Free PMC article.
From ICU Syndromes to ICU Subphenotypes: Consensus Report and Recommendations For Developing Precision Medicine in ICU.
Gordon AC, Alipanah-Lechner N, Bos LD, Dianti J, Diaz JV, Finfer S, Fujii T, Giamarellos-Bourboulis EJ, Goligher EC, Gong MN, Karakike E, Liu V, Lumlertgul N, Marshall JC, Menon DK, Meyer NJ, Munroe ES, Myatra SN, Ostermann M, Prescott HC, Randolph AG, Schenck EJ, Seymour CW, Shankar-Hari M, Singer M, Smit MR, Tanaka A, Taccone FS, Thompson BT, Torres LK, Van der Poll T, Vincent JL, Calfee CS. Gordon AC, et al. Among authors: giamarellos bourboulis ej. Am J Respir Crit Care Med. 2024 Apr 30. doi: 10.1164/rccm.202311-2086SO. Online ahead of print. Am J Respir Crit Care Med. 2024. PMID: 38687499
Obesity, Inflammation, and Clinical Outcomes in COVID-19: A Multicenter Prospective Cohort Study.
Hutten CG, Padalia K, Vasbinder A, Huang Y, Ismail A, Pizzo I, Machado Diaz K, Catalan T, Presswalla F, Anderson E, Erne G, Bitterman B, Blakely P, Giamarellos-Bourboulis EJ, Loosen SH, Tacke F, Chalkias A, Reiser J, Eugen-Olsen J, Banerjee M, Pop-Busui R, Hayek SS. Hutten CG, et al. Among authors: giamarellos bourboulis ej. J Clin Endocrinol Metab. 2024 Apr 18:dgae273. doi: 10.1210/clinem/dgae273. Online ahead of print. J Clin Endocrinol Metab. 2024. PMID: 38635301
HEPARIN-BINDING PROTEIN LEVELS PREDICT UNFAVORABLE OUTCOME IN COVID-19 PNEUMONIA: A POST HOC ANALYSIS OF THE SAVE TRIAL.
Kyriazopoulou E, Dalekos GN, Metallidis S, Poulakou G, Papanikolaou IC, Tzavara V, Argyraki K, Alexiou Z, Panagopoulos P, Samarkos M, Chrysos G, Tseliou A, Milionis H, Sympardi S, Vasishta A, Giamarellos-Bourboulis EJ. Kyriazopoulou E, et al. Among authors: giamarellos bourboulis ej. Shock. 2024 Mar 1;61(3):395-399. doi: 10.1097/SHK.0000000000002315. Epub 2024 Jan 19. Shock. 2024. PMID: 38517242
502 results